Variable | n (%) (n=59 patients) |
Age | |
≤16 years | 12 (20.3) |
>16 years | 47 (79.7) |
Gender | |
Male | 44 (74.6) |
Female | 15 (25.4) |
Body mass index | Mean 25.4±5.9 (range: 16.33–45.2) |
Diagnoses | |
Behçet’s disease | 38 (64.4) |
Idiopathic panuveitis | 9 (15.3) |
Chronic recurrent VKH | 4 (6.8) |
Idiopathic intermediate uveitis | 3 (5.1) |
Idiopathic anterior uveitis | 3 (5.1) |
Sarcoidosis | 1 (1.7) |
Diffuse subretinal fibrosis syndrome | 1 (1.7) |
Type of biologic therapy | |
Infliximab | 36 (61) |
Adalimumab | 14 (23.7) |
Rituximab | 9 (15.3) |
COVID-19 test | |
Positive | 9 (15.3) |
Negative | 50 (84.7) |
VKH, Vogt-Koyanagi-Harada disease.